Emergex granted membership of the Social Stock Exchange

London, February 20th 2017 – the Social Stock Exchange (www.socialstockexchange.com) – society’s market for impact investing – has today announced that Emergex (www.emergexvaccines.com) has been approved as a member following the ratification of its impact report by the independent Admissions Panel.

Pandemics disproportionately affect people in developing countries.  Emergex will address this by offering a novel synthetic vaccine technology that is ideally suited to the low resource environments where these infections occur. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defense against existing and newly emerging infectious outbreaks.

The Social Stock Exchange enables its accredited impact issuers to raise capital or undertake primary or secondary listings of debt or equity instruments.

About the Social Stock Exchange

The Social Stock Exchange provides access to the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities. The aim of the exchange is to help these businesses connect with investors and unlock capital at scale.  All issuer member companies must meet a rigorous set of criteria before joining, including the publication of an Impact Report.

The Social Stock Exchange has an agreement with NEX Exchange (formerly ISDX) to operate the Social Stock Exchange branded market segment for impact businesses.

The Social Stock Exchange Ltd (FRN: 625231) is an appointed representative of Kession Capital Limited (FRN: 582160) which is authorised and regulated by the Financial Conduct Authority (“FCA”) in the UK.

NEX is a Recognised Investment Exchange operating a regulated market and a growth market and provides a secondary market trading facility.  NEX is supervised by the FCA.

For more information please contact:


Tony Cross
Monk Communications
T: +44 7973 284 749
E: tony@monkcommunications.com


Tomás Carruthers
Social Stock Exchange
T: +44 (0) 203 608 8056
E: t.carruthers@socialstockexchange.com


Storme Moore-Thornicroft
E: smt@emergexvaccines.com